According to a new report from The Wall Street Journal, Google's (now Alphabet's) Life Sciences group is adding another company to a growing list of partners that are helping the group explore new technologies for disease treatment and prevention. Specifically, the Life Sciences group, led by the to-be-CEO Andrew Conrad under Alphabet, has agreed to work with European pharmaceutical company Sanofi on new ways to treat and monitor diabetes...
Google Inc. said Monday its health-care-research unit agreed to work with European pharmaceutical major Sanofi SA on new ways to monitor and treat diabetes.
The companies declined to say how much they are investing in the partnership.
Sanofi is a leading maker of diabetes medication, as well as many other drugs. Google's Life Sciences division is working on small, connected medical devices to continuously collect diabetes-related data, as well as software that learns from the information to find new treatments. Diabetes is expected to affect 592 million people world-wide by 2035, according to the International Diabetes Federation.
Pascale Witz, head of Sanofi's Global Diabetes and Cardiovascular Care business, is leading the collaboration.
A day after Life Sciences was announced be becoming its own division under the new Alphabet conglomerate, DexCom announced that it would be partnering with the group to work on diabetes-related technology as well. Specifically, this partnership is bringing the development of a "cheap, disposable device the size of a Band-Aid that can be worn on the skin and send blood-sugar measurements to a smartphone, as well as Google."
The newly-formed partnership with Sanofi sounds similar:
[Andrew Conrad] said Sanofi's experience making insulin—which controls diabetics' blood sugar levels—might help Google design smaller, Internet-connected devices that could automatically suggest or adjust insulin dosages in response to blood-sugar readings or doctor-prescribed patient exercise regimes.
We'll have to wait and see what comes of these partnerships — it could be several years before anything materializes. But lately, the developments of Life Sciences have become more public. Earlier this year, the group debuted (via Bloomberg), a new health-tracking wristband capable of monitoring heart rate, heart rhythm, skin temperature, and other useful information such as light exposure and noise levels.
WordPress.com
[New post] Alphabet’s Life Sciences division partners with Sanofi, leading maker of diabetes medication
Join This Site Show Conversion CodeHide Conversion Code Show EmoticonHide Emoticon
Note: only a member of this blog may post a comment.